5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Cohance Lifesciences Ltd.

•
cohance.comBSE: 543064NSE: COHANCE
Market Cap₹ 17,194 Cr.
Current Price
High / Low₹ 1,039 / 267
Stock P/E96.8
Book Value₹ 117
Price to Book2.59
Dividend Yield0.00 %
ROCE7.4 %
ROE5.3 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Promoters have been increasing their shareholding - up 7.4pp over 2 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.43x)
  • Company comfortably covers its interest (15.0x coverage)
  • Institutional investors have been accumulating - FII+DII up 8.0pp
  • Company generates healthy free cash flow

CONS

  • Recent results are weak - TTM profit is down 48.5% versus prior year
  • Operating margins have contracted to 22.4% from 47.7%
  • Company has delivered a poor profit growth of -5.8% over past five years
  • Valuation is stretched - P/E of 96.8 is well above its own 5-year median (58.1)
  • Working capital days have increased from 154 to 209 days
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1899.8037.69455825.660.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9305.0084.45247018.510.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4913.0085.68186874.730.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1155.0025.53115211.690.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1395.9533.46112773.000.93785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1868.2592.32100943.830.11362.07123.942026.3129.1018.2031.50
7.LUPIN2105.0017.4196254.460.861416.9816.018276.8934.2828.8629.59
8.MANKIND2322.0546.9595911.140.04574.0929.124030.5912.8913.2426.30
9.DRREDDY1145.0029.6695570.850.70435.60-69.108099.80-5.2113.7510.63
10.AUROPHARMA1658.0025.7095397.650.241032.0325.229150.3517.4412.7620.54
11.GLENMARK2462.0038.6569483.710.10482.83927.884018.4831.3520.3520.03
12.COHANCE449.40161.8617193.920.00-45.19-197.39422.26-23.136.120.27
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3442252132534885946537694844984825683,599
1731271441803633914215463793673794513,698
Operating Profit171986973125204233223104131103117-100
OPM %49.61%43.65%32.45%28.99%25.65%34.24%35.62%28.98%21.55%26.29%21.34%20.54%-2.76%
10141417191621-85261-17122
Interest2122109107755521
Depreciation111111173135384331313338343
Profit before Tax168101707110317520616671121655622
Tax %25.86%25.69%24.66%24.87%26.82%20.65%25.33%25.86%26.00%21.89%27.72%38.77%36.20%
Net Profit124755253751391541235394473514
4.882.942.062.091.983.654.043.221.382.461.240.900.04

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
3788341,0101,3201,3301,0512,5042,0301,907
2064495677387396451,7201,5761,567
Operating Profit172385443582591406784454340
OPM %45.40%46.15%43.88%44.11%44.41%38.60%31.31%22.38%17.84%
118141884557491522
Interest322129137372218
Depreciation112432394355147134137
Profit before Tax158358414722579400650314245
Tax %30.78%24.47%25.44%22.75%25.34%25.96%24.44%27.08%27.47%
Net Profit109270309558433296491229178
EPS0.0010.6112.1221.9216.9911.6419.295.98—
Dividend Payout %—23.56%16.50%22.81%35.31%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
15%
3 Years:
15%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
-6%
3 Years:
-19%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
-55%

RETURN ON EQUITY

10 Years:
—
5 Years:
21%
3 Years:
12%
Last Year:
5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2020

Sep 25

1:1

Employees Stock Option Plan & Bonus issue & Increase in Authorised Capital Inter alia, approved : 1. Issue of Bonus Shares The Board of Directors has considered, approved and recommended issue of (1:1) one Bonus Share for every one equity share held by the equity shareholders of the Company. The bonus issue of equity shares is subject to the approval of the shareholders in the ensuing annual general meeting and any other applicable statutory and regulatory approvals, as may be required. 2. The Second Annual General Meeting of the Company will be held on Monday the 14th day of September, 2020 at 11.30 a.m. IST. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights of the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared, if any, after the issue and allotment of such Bonus Shares. 3. The Board of Directors has considered and approved increase in the Authorized Share Capital from Rs. 20.10 crores divided into 20.10 crores equity shares of Rs. 1/- each to Rs. 40.00 crores divided into 40.00 crores equity shares of Rs. 1/- each and consequential alteration in the Memorandum of Association of the Company, subject to the approval of shareholders of the Company. 4. The Board of Directors also approved granting of 10,00,000 (ten lakh only) Employee Stock options of Rs.1/- each under Suven Pharma Employee Stock Option Scheme 2020 (SPLESOP 2020) to the eligible employees of the Company and recommended to the members for their approval in the ensuing Annual General Meeting.

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital013252525252538
5787701,0401,4951,7242,0014,1614,424
8318614296706024090
Trade Payables5471831066742259260
10219117121921786352301
Total Liabilities8161,2301,4611,9422,1032,2145,0375,113
2713574415345126702,0792,288
Capital Work in Progress1111029630165179330144
72764266007108931,1171,187
157175201283311231455540
00000134730642
Cash & Bank1314103346223620
25730728646235886290293
Total Assets8161,2301,4611,9422,1032,2145,0375,113

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
83445438422639376686390
Cash from Investing-65-367-258-90-237-362-455-204
Cash from Financing269-76-156-243-40-310-203
111-42313-26-79-18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.1050.1050.1050.1066.4157.4957.4957.4957.49
9.8010.7010.8411.057.236.516.015.596.50
17.4216.9516.6716.6011.4020.8121.5721.7920.09
0.010.010.010.010.010.010.010.010.01
22.6722.2522.3722.2314.9515.1714.9215.1215.92

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-05
General Updates

2026-09-05 - Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection

2026-09-03
Press Release

2026-09-03 - Cohance Lifesciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Press Release ".

2026-09-03
Committee Meeting Updates

2026-09-03 - Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026.

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

2026-08-27
Copy of Newspaper Publication

2026-08-27 - Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-26
General Updates

2026-08-26 - Cohance Lifesciences Limited has informed the Exchange about submission of BRSR

2026-08-26
General Updates

2026-08-26 - Cohance Lifesciences Limited has informed the Exchange about Integrated Annual Report 2026

2026-08-26
Shareholders meeting

2026-08-26 - Cohance Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on 17 September 2026

2026-08-13
Credit Rating- Others

2026-08-13 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others

News

Recent coverage and analyst commentary for COHANCE

Loading news…

🤖

AI Stock Analyst

Cohance Lifesciences Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login